Literature DB >> 1582596

Immunoglobulin G (IgG), IgG1, and IgG2 determinations from endoscopic biopsy specimens in control, Crohn's disease, and ulcerative colitis subjects.

J Rüthlein1, M Ibe, W Burghardt, J Mössner, I O Auer.   

Abstract

Acute exacerbations of chronic inflammatory bowel disease (ulcerative colitis and Crohn's disease) are characterised by an increase in immunoglobulin G (IgG) positive cells in the mucosa, whereas uninflamed mucosa of inflammatory bowel disease patients displays only moderately increased or normal numbers of these cells. Previous data suggest that acute exacerbations of ulcerative colitis and Crohn's disease can be distinguished by different IgG subclass expression of mucosal immunocytes and a different IgG subclass production pattern of lamina propria lymphocytes. A procedure to obtain enough intestinal mononuclear cells from biopsy specimens to measure in vitro IgG and IgG1 production in control subjects and various patient groups has been established. IgG2 could be measured in Crohn's disease and ulcerative colitis only, as the concentrations in control subjects were below the sensitivity of the ELISA method. We found that IgG and IgG1 production correlated with the degree of local inflammation in both diseases, even in slightly inflamed mucosa, compared with control subjects. The proportion of IgG1 subclass was significantly increased in severely inflamed mucosa of both ulcerative colitis and Crohn's disease patients. A major difference between Crohn's disease and ulcerative colitis mucosa is apparent in mild or no inflammation. In Crohn's disease mucosa in remission, the IgG1/IgG ratio is comparable with that in controls, yet ulcerative colitis mucosa still displays significantly increased proportions of IgG1. In addition, the IgG2/IgG ratio is 0.12 in ulcerative colitis and 0.19 in Crohn's disease patients. The results show the dependence of local IgG and IgG1 production on the degree of inflammation and that an increase in subclass IgG1 in ulcerative colitis is present at all stages, including remission. These findings support the hypothesis that different immunoregulatory mechanisms are involved in Crohn's disease and ulcerative colitis. Environmental stimuli or genetic background may be responsible for the observed differences.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1582596      PMCID: PMC1374068          DOI: 10.1136/gut.33.4.507

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  26 in total

1.  Assessment of severity in colitis: a preliminary study.

Authors:  J E Lennard-Jones; J K Ritchie; W Hilder; C C Spicer
Journal:  Gut       Date:  1975-08       Impact factor: 23.059

2.  Cortisone in ulcerative colitis; final report on a therapeutic trial.

Authors:  S C TRUELOVE; L J WITTS
Journal:  Br Med J       Date:  1955-10-29

Review 3.  Immunobiology and immunopathology of human gut mucosa: humoral immunity and intraepithelial lymphocytes.

Authors:  P Brandtzaeg; T S Halstensen; K Kett; P Krajci; D Kvale; T O Rognum; H Scott; L M Sollid
Journal:  Gastroenterology       Date:  1989-12       Impact factor: 22.682

4.  Immunoglobulin production by isolated intestinal mononuclear cells from patients with ulcerative colitis and Crohn's disease.

Authors:  K C Wu; Y R Mahida; J D Priddle; D P Jewell
Journal:  Clin Exp Immunol       Date:  1989-10       Impact factor: 4.330

5.  Spontaneous secretion of IgG subclasses by intestinal mononuclear cells: differences between ulcerative colitis, Crohn's disease, and controls.

Authors:  M G Scott; M H Nahm; K Macke; G S Nash; M J Bertovich; R P MacDermott
Journal:  Clin Exp Immunol       Date:  1986-10       Impact factor: 4.330

6.  Disordered regulation of the in vitro immunoglobulin synthesis by intestinal mononuclear cells in Crohn's disease.

Authors:  H W Verspaget; A S Peña; I T Weterman; C B Lamers
Journal:  Gut       Date:  1988-04       Impact factor: 23.059

7.  Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease.

Authors:  P Gomes; C du Boulay; C L Smith; G Holdstock
Journal:  Gut       Date:  1986-01       Impact factor: 23.059

8.  Epithelial deposition of immunoglobulin G1 and activated complement (C3b and terminal complement complex) in ulcerative colitis.

Authors:  T S Halstensen; T E Mollnes; P Garred; O Fausa; P Brandtzaeg
Journal:  Gastroenterology       Date:  1990-05       Impact factor: 22.682

9.  Mucosal subclass distribution of immunoglobulin G-producing cells is different in ulcerative colitis and Crohn's disease of the colon.

Authors:  K Kett; T O Rognum; P Brandtzaeg
Journal:  Gastroenterology       Date:  1987-11       Impact factor: 22.682

10.  T lymphocyte subpopulations and immunoglobulin-containing cells in the colonic mucosa of ulcerative colitis; a morphometric and immunohistochemical study.

Authors:  K Kobayashi; H Asakura; Y Hamada; T Hibi; M Watanabe; T Yoshida; N Watanabe; S Miura; S Aiso; M Tsuchiya
Journal:  J Clin Lab Immunol       Date:  1988-02
View more
  9 in total

Review 1.  Developmental regulation of immunoglobulin mRNA processing and the IgA response: establishing a paradigm.

Authors:  D A Lebman; J H Coyle
Journal:  Immunol Res       Date:  1999       Impact factor: 2.829

2.  B1a lymphocytes in ulcerative colitis.

Authors:  Lino Polese; Giuseppe De Franchis; Marco Scarpa; Giacomo C Sturniolo; Cesare Ruffolo; Lorenzo Norberto; Mauro Frego; Davide F D'Amico; Imerio Angriman
Journal:  Int J Colorectal Dis       Date:  2007-03-20       Impact factor: 2.571

3.  Distal proctocolitis and n-3 polyunsaturated fatty acids (n-3 PUFAs): the mucosal effect in situ.

Authors:  Y Z Almallah; S W Ewen; A El-Tahir; N A Mowat; P W Brunt; T S Sinclair; S D Heys; O Eremin
Journal:  J Clin Immunol       Date:  2000-01       Impact factor: 8.317

4.  Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria.

Authors:  A Macpherson; U Y Khoo; I Forgacs; J Philpott-Howard; I Bjarnason
Journal:  Gut       Date:  1996-03       Impact factor: 23.059

5.  Immunoglobulin G subclass distribution of anti-endothelial cell antibodies (AECA) in patients with ulcerative colitis or Crohn's disease.

Authors:  D Aldebert; E Masy; D Reumaux; G Lion; J F Colombel; P Duthilleul
Journal:  Dig Dis Sci       Date:  1997-11       Impact factor: 3.199

6.  Decreased mucosal IgA levels in ileum of patients with chronic ulcerative colitis.

Authors:  L Cicalese; R H Duerr; M A Nalesnik; P F Heeckt; K K Lee; W H Schraut
Journal:  Dig Dis Sci       Date:  1995-04       Impact factor: 3.199

Review 7.  B cell class switching in intestinal immunity in health and disease.

Authors:  Aaron Fleming; Tomas Castro-Dopico; Menna R Clatworthy
Journal:  Scand J Immunol       Date:  2022-01-12       Impact factor: 3.889

8.  Distinct patterns of naive, activated and memory T and B cells in blood of patients with ulcerative colitis or Crohn's disease.

Authors:  H Rabe; M Malmquist; C Barkman; S Östman; I Gjertsson; R Saalman; A E Wold
Journal:  Clin Exp Immunol       Date:  2019-04-08       Impact factor: 4.330

9.  Mucosal IgG in inflammatory bowel disease - a question of (sub)class?

Authors:  Tomas Castro-Dopico; Menna R Clatworthy
Journal:  Gut Microbes       Date:  2019-09-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.